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ABSTRACT
Increased physiological levels of oxysterols are
major risk factors for developing atherosclerosis
and cardiovascular disease. Lipid-loaded macro-
phages, termed foam cells, are important during
the early development of atherosclerotic plaques.
To pursue the hypothesis that ligand-based modu-
lation of the nuclear receptor LXRa is crucial for cell
homeostasis during atherosclerotic processes, we
analysed genome-wide the action of LXRa in foam
cells and macrophages. By integrating chromatin
immunoprecipitation-sequencing (ChIP-seq) and
gene expression profile analyses, we generated a
highly stringent set of 186 LXRa target genes.
Treatment with the nanomolar-binding ligand
T0901317 and subsequent auto-regulatory LXRa
activation resulted in sequence-dependent sharpen-
ing of the genome-binding patterns of LXRa.
LXRa-binding loci that correlated with differential
gene expression revealed 32 novel target genes
with potential beneficial effects, which in part ex-
plained the implications of disease-associated
genetic variation data. These observations identified
highly integrated LXRa ligand-dependent transcrip-
tional networks, including the APOE/C1/C4/C2-gene
cluster, which contribute to the reversal of choles-
terol efflux and the dampening of inflammation
processes in foam cells to prevent atherogenesis.
INTRODUCTION
Cardiovascular and metabolic disorders have become an
enormous burden for human health. Homeostasis of chol-
esterol at the blood vessel wall is important to cope with
elevated cholesterol levels that contribute to increased
rates of atherosclerosis and cardiovascular disease (1). A
key event in the development of atherosclerosis consists of
the uncontrolled uptake of oxidized low-density lipopro-
teins (oxLDL) by macrophages recruited at the
subendothelial space of vessel walls (2). In concert with
local inflammatory reactions, this process leads to the for-
mation of lipid-loaded macrophages termed foam cells (3).
The liver x (nuclear) receptors, LXRa and LXRb, are
ligand-dependent factors that regulate cholesterol homeo-
stasis and reverse cholesterol transport; hence, they are
interesting drug targets for treating cardiovascular
diseases (4). Oxysterols are natural ligands and activators
of LXRa (5), which is the predominant LXR subtype
required for the full anti-atherogenic action of LXR
agonists in inhibiting atherosclerosis (6). Evolutionary
analysis of the sequences of both LXR subtypes suggested
that a single LXR gene duplicated during mammalian evo-
lution (7) and resulted in one general and one more
specialized factor. Consistent with this hypothesis,
LXRb was found to be ubiquitously expressed, whereas
LXRa is more restricted to cell types that modulate chol-
esterol and fatty acid metabolism, most importantly in
liver and macrophages (8). Hypothesis-driven research
revealed important insights, including LXRa regulation
at selected genomic loci of target genes, such as the
ATP-binding cassette transporters ABCA1 and ABCG1,
or apolipoprotein E, to understand mechanistic aspects
of foam cell development and atherosclerosis (9).
Here, we applied genome-wide analysis to shed light on
the contribution of ligand-based LXRa regulation to these
processes. We performed integrative genomic analyses
with the aim to decipher LXRa-dependent functional
features and transcriptional regulation pathways,
including the effects of anti-atherosclerotic drug treat-
ment. Key networks determined by LXRa activation led
to biological function such as counteracting lipid-overload
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in macrophages, which could in principle not be fully
derived from single gene events and analysis thereof.
To analyze the role of LXRa modulation in atheroscler-
osis and related diseases we used a well-validated human
macrophage and foam cell model and applied the efficient
synthetic LXR agonist T0901317.
MATERIALS AND METHODS
Cell models
Human monocytic leukaemia THP1 cells were maintained
in RPMI 1640 medium (Sigma-Aldrich) supplemented
with 10% fetal bovine serum (FBS, Biochrom) and
differentiated for 48 h using 10e-8 M phorbol 12-myristate
13-acetate (PMA, Sigma-Aldrich). Human primary
macrophages were isolated from at least four individual
buffy coats donated by healthy volunteers (kindly
provided by DRK-Blutspendedienst Ost Gemeinnu¨tzige
GmbH Institut Berlin). Peripheral blood monocytes
(PBM) were isolated from buffy coats with Ficoll Paque
and MACS Monocyte Isolation Kit II with MACS LS
columns (Miltenyi Biotec). Monocytes were differentiated
for 7 days. Primary and THP1 macrophages were treated
similarly either with 0.01% dimethylsulfoxide (DMSO) or
1 mM T0901317 (Sigma-Aldrich) for 24 h. Foam cell for-
mation was induced by 100 mg/ml oxLDL (Autogen
Bioclear UK Ltd) for 48 h and subsequently treated
with 0.01% DMSO or 1 mM T0901317 for 48 h.
Cholesterol loading and treatment was controlled by Oil
Red O staining; detailed cholesterol composition was
assessed with the fluorometric method of Amplex Red
Cholesterol Assay Kit (Invitrogen).
LXR knockdown
For siRNA-mediated LXRa/b-knockdown, differentiated
THP1 cells were transfected with TransIT-TKO transfec-
tion reagent (Mirus) and 15 nM LXRa Silencer Validated
siRNA (ID 5458) and 15 nM LXRb Silencer Select
Validated siRNA (ID s14684) or 30 nM Silencer Select
Negative Control #1 (all from Ambion). Transfection
was carried out for 48 h followed by treatment of macro-
phages and foam cells with 10 mM T0901317 or 0.1%
DMSO for 24 h.
Western blotting
Western blotting was performed with commercial
antibodies against LXRa [Abcam, ab 41902, (10,11)],
LXRb [Abcam, ab56237, (12)], RXRa (Santa Cruz
Biotechnology, sc-774 X) and b-actin (Santa Cruz
Biotechnology, sc-47778, C4). Secondary antibodies were
horseradish peroxidase (HRP)-labelled anti-mouse and
anti-rabbit (Santa Cruz Biotechnology). Densitometry
was performed using ImageQuant TL (GE Healthcare).
Chromatin immunoprecipitation and sequencing
Chromatin immunoprecipitation (ChIP) was performed
with Diagenode’s Transcription Factor ChIP Kit
(Diagenode). For immunoprecipitation, we used the
well-validated antibodies against LXRa (Abcam, ab
41902), LXRb (Abcam, ab56237), H3K4me3 (pAB-003-
050, Diagenode), anti-H4K20me1 (ab9051, Abcam) and
negative control IgG (kch-819-015, Diagenode). For one
LXRa ChIP-seq reaction, we pooled at least four individ-
ual ChIP reactions. Sequencing of LXRa was performed
twice (individual biological replicates) for macrophages
and T0901317 treated macrophages. Sequence reads of
36 bp were obtained using the second-generation
Genome Analyzer and the Solexa Analysis Pipeline
(Illumina). Reads were mapped to human genome
assembly (February 2009, GRCh37/hg19) using Bowtie
(13). Sequencing data were submitted to EBI and can be
accessed via www.ebi.ac.uk/ena/data/view/ERP001502.
Peak calling and LXRa binding profiles were generated
genome-wide using the model based-analysis of
ChIP-seq algorithm [MACS, (14)]. Validation of seq-
uencing results was performed with ChIP–quantitative
polymerase chain reaction (qPCR) (SYBR Green PCR
Master Mix, Applied Biosystems). The relative occupancy
of the immunoprecipitated factor at a locus was estimated
using the following equation: 2 e (Ct inputCt ChIP).
LXRa ChIP qPCR was normalized against IgG ChIP
qPCR of the same locus. Detailed description of ChIP
procedure, peak calling and filtering can be found in the
Supplementary Methods and Supplementary Datasets S1.
Peak analysis
To compare different ChIP-seq lanes and to detect differ-
ential LXRa binding across investigated cell models, we
performed LXRa peak-enrichment normalization (15) for
all cell models. Differential binding events were based on a
change of 1.5-fold. For visualization, raw tag data was
loaded to seqMINER (16). Genomic distributions were
determined using the Cis-regulatory Element Annotation
System (17).
Annotation of genes controlled by nearby peaks
As we assumed that one LXRa-binding site can regulate
multiple surrounding target genes (18,19), we decided to
annotate all potential LXRa target genes with a maximal
distance of 200 kb from peak centre (Supplementary
Datasets S2). Therefore, we used the Peak Center
Annotation script (peak2gene) from the Cistrome
Analysis Pipeline (cistrome.org). Gene definitions were
taken from the UCSC Genome Browser’s RefGene
table (20).
Formaldehyde-assisted isolation of regulatory elements
followed by sequencing
Formaldehyde-assisted isolation of regulatory elements
(FAIRE) was performed as described previously (21).
For relative openness analysis, enrichment intensities
were extracted, quantile normalized and averaged for
each genomic region. Detailed descriptions can be found
in Supplementary Methods.
LXRa motif analyses
Motif search was performed de novo with top 100 bound
sequences for each defined peak set individually using the
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MEME-ChIP tool from MEME suite [http://meme.sdsc.
edu, (22)] with default settings. Derived motifs with
P-value of< 10e-7 were scanned using available position
weight matrices from the Transfac database (23). Motif
distribution in all LXRa peak set sequences was
determined by the find motif tool FIMO (MEME suite
tool) with threshold P-value of 10e-4.
Reporter gene assays
Reporter gene assays were performed with natural and
mutated LXR response elements (LXREs). Therefore,
five copies of the LXREs were cloned into pGL4.31
vector (Promega) with the In-Fusion HD EcoDry
cloning system (Clontech Takara Bio Europe). Full-
length LXRa and RXRa were cloned from cDNA frag-
ments (Source BioScience clone IRATp970C0271, Gene
ID: 7376 and clone IOH39435, Gene ID: 6256) into
pBIND vector (Promega). Detailed descriptions can be
found in supplementary experimental procedures. For
reporter gene analysis, HEK293T cells were co-transfected
with the pGL4.31–LXRE–Luc, pBIND–LXRa and
pBIND–RXRa in 0.25% Lipofectamine (Invitrogen) for
4 h and subsequently treated with 10 mM T0901317 or
0.1% DMSO for 24 h. Reporter activity was determined
with Dual Luciferase Reporter System (Promega).
Activity was measured in relative luciferase units and
finally visualized as fold-change of T0901317 treatment
from vehicle control.
Gene expression
RNA extraction, microarray and quantitative PCR
analyses were performed as described elsewhere (24).
Differential expression analysis was performed on
background subtracted data with cubic spline normaliza-
tion and Benjamini Hochberg false discovery rate (FDR)
correction. Significant data were considered to have a de-
tection P-value of <0.01 and differential P-value of <0.05.
Gene expression data were submitted in MIAME-
compliant form to the ArrayExpress database under
accession number E-MTAB-1106 (www.ebi.ac.uk/
arrayexpress). Detailed descriptions and gene lists can be
found in Supplementary Methods and Supplementary
Datasets S3.
Correlation analyses
For correlation, we compared differentially expressed
genes (versus vehicle treated macrophages) with binding
site associated genes. For visualization, we chose to plot
the normalized LXRa peak enrichment and differential
gene expression sorted in 4 up- and 4 down- quantiles
according to the expression fold-change. For gene
activity prediction, we determined promoter-specific
changes of H3K4me3, H4K20me1 and chromatin accessi-
bility at genes with a nearby binding (25). Further, we
generated a relative histone and FAIRE-seq signal of
our cell models versus untreated macrophage and built
the mean signal ±1.5 kb of the target gene transcription
start site (TSS) and plotted the mean signal and differen-
tially expressed genes in quintiles for each cell model (26).
For prediction, we chose the mean signal fold-change of
expression quantile 4. To determine a significant impact of
LXRa binding on gene expression, we correlated LXRa
peak locations and differential expression of nearby genes
and compared this with a randomly shuffled peak set.
Initially, we investigated this relationship as described by
Boeva et al. (27). The significance of this spatial
relationship was tested by three statistical hypothesis
tests, hypergeometric test, Kolmogorov-Smirnov test
(K-S test) and empirical cumulative distribution function
(ECDF)-based test (Anderson-Darling test) (28).
Gene ontology analysis
Gene ontology (GO)-enrichment analysis was performed
using the Database for Annotation, Visualization and
Integrated Discovery [DAVID, http://david.abcc.ncifcrf.
gov/,(29)] for the model-specific and knockdown-validated
LXRa target genes with a binding site. We performed
functional annotation clustering for GO term
Bioprocess_FAT with highest classification stringency.
Pathway analysis
Pathway analysis was also performed with DAVID
analysing the Kyoto Encyclopedia of Genes and
Genomes (KEGG) and BIOCARTA pathways with the
functional annotation chart option. Information on regu-
lation of lipid metabolism by peroxisome proliferators-
activated receptor alpha (PPARa) was extracted from
Reactome pathway database [www.reactome.org, (30)].
Pathway analysis for T0901317-specific LXRa target
genes in foam cells was performed with Ingenuity
Pathways Analysis [IPA, www.Ingenuity.com, (31)]. We
performed core analysis using the Ingenuity Knowledge
Base as reference set and considered direct and indirect
relationships with high or experimentally observed
confidence.
Association of LXRa-binding sites with genome-wide
association studies
Correlation of LXRa-binding data with genome-wide as-
sociation studies (GWAS) was processed by overlapping
the NHGRI GWAS catalogue (32) single-nucleotide poly-
morphism (SNPs) positions with our defined LXRa-
binding sites. We chose a P-value threshold of <10e-5.
Additionally, we controlled that the LXRa-binding sites
of interest were within the linkage disequilibrium (LD)
block [DistiLD Database, (33)] of the SNP. Further, we
considered just LXRa peak-associated genes that were
also reported in the GWAS. Detailed list can be found
in Supplementary Datasets S4.
Functional network analysis
Interaction networks were derived from the
FANTOM4-EdgeExpress Database (34) and STRING
(35). Networks were visualized using Cytoscape (36).
Differentiation between already known and new LXRa
target genes and interactors were done with BIOGRID,
NEXTBIO, Nuclear Receptor Resource [(37,38); http://
nrresource.org] databases and most recent publications
on LXRa (19,39).
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Statistical analysis
The Student’s t-test was used to calculate the statistical
significance. When multiple samples were analyzed the
ANOVA test was applied followed by Dunnett’s
multiple comparison test with P< 0.05 considered as
statistically significant. All results represent the
mean±standard deviation.
RESULTS
LXRa binding is highly ligand dependent in THP1
and human primary macrophage models
Knowledge about the binding of LXRa to the human
genome is required to lay the foundation for deciphering
specific sets of regulatory regions of this ligand-dependent
nuclear receptor. LXRa is by nature a flexible sensor for
diverse metabolites in the human body, which can respond
quickly to changing ligand concentrations. To generate
stringent data sets for further analyses, we considered
only LXRa-binding sites, which resulted in differential
gene expression and were LXR knockdown sensitive
(Supplementary Figure S1A).
First, we examined the amount of LXRa and LXRb
proteins and their heterodimerization partner RXRa.
Because of ligand-based activation in human
macrophages, LXRa is increasingly expressed in an
auto-regulatory fashion, whereas comparably low
proteins amounts of the LXRb subtype and RXRa
showed no significant change (Figure 1A, Figure 1B and
Supplementary Figure S1B). Notably, mouse macro-
phages do not show a feed-forward loop of LXRa expres-
sion (40), indicating that activation of LXRa in human
cells differs strikingly from mouse foam cells. Cholesterol
loading and beneficial effects of T0901317 were further con-
firmed by Oil red O staining (Supplementary Figure S1C)
and cholesterol composition analysis (Figure 1C). To deter-
mine LXRa binding in THP1-derived macrophages and
foam cells in presence and absence of synthetic LXRa
ligand T0901317, we applied ChIP using a well-validated
and previously applied antibody (10,41) followed by mas-
sively parallel deep sequencing. Macrophages and
T0901317-treated macrophages were sequenced in biolo-
gical duplicates and reached correlation values of r=0.98
and r=0.92, respectively (Supplementary Figure S1D). In
ligand-free macrophages with low amounts of LXRa
(Figure 1B), its genome-wide enrichment at potential
binding sites was mostly below the defined threshold for
detection of significantly enriched LXRa-binding sites
(Supplementary Figure S1E). To exclude any bias during
ChIP-seq data processing, we selected LXRa-binding sites
and validated successfully 21 ChIP-seq peaks by ChIP–
Figure 1. In human macrophage and foam cell models, LXRa is regulated in an auto-regulatory fashion. (A) Sketch of LXRa auto-regulatory
function. LXRa, in complex with RXRa and a specific ligand, is bound to a direct repeat of 4 (DR4) response elements in front of LXR gene locus.
Ligand-dependent activation of LXR gene expression is regulated via a feed-forward loop mechanism. (B) Western blot analysis of LXRa, LXRb,
RXRa and ACTB (b-actin) in macrophages and foam cells in the presence and absence of T0901317. (C) Cholesterol composition analysis in
macrophages, foam cells and T0901317-treated foam cells expressed as micromolar cholesterol per gram protein. Total cholesterol (black), free
cholesterol (grey) and esterified cholesterol (white). The average from six biological replicates with standard errors of mean is shown. Cross indicates
statistically significant, P< 0.05. (D) ChIP–qPCR validation of LXRa and LXRb enrichment at ABCA1 LXRE locus in THP1-derived macrophage
models and LXRa in human PBM-derived models relative to IgG control.
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qPCR analysis, including confirmation of the extremely low
abundance of LXRa in the absence of ligand (Figure 1D
and Supplementary Figure S1F and G). Characteristically,
LXRa binding was highly induced by its synthetic ligand
T0901317 in contrast to ligand-independent, constitutive
binding of the LXRb subtype. As LXRa was 38 times
more abundant in T0901317-treated foam cells than its
b-subtype, we consistently observed up to 80-fold enrich-
ment of LXRa, whereas we found only 2.5-fold enrichment
for LXRb, as detected at the ABCA1 LXR response
element (LXRE) locus (Figure 1D and Supplementary
Table S1).
To validate the THP1 model, we used human
PBM-derived macrophages and produced foam cells
thereof, and obtained similar LXRa-binding profiles
(Figure 1D). Interestingly, we detected spurious ligand-
free LXRa-binding background only in PBM-derived
macrophages, indicating experimentally interfering lipids
observed in the donor blood. THP1 cells were required to
gain sufficient and standardized material for further
analyses and were, therefore, the experimental resource
of choice.
Three sets of LXRa genomic loci define gene regulation in
macrophages and foam cells
To understand oxLDL- and/or T0901317-induced cell-
specific and shared binding events of LXRa, we applied
comparative ChIP-Seq analyses (15) and could categorize
three different sets of LXRa genome binding (Figure 2A).
Fifty-five per cent of LXRa peaks (1459 peaks) were dif-
ferent among cell models. Thereof, 29% (769 peaks)
showed prominent enrichment in T0901317 treated
macrophages and foam cells (T0901317 specific set), and
we observed an enrichment of 26% (690 peaks) of LXRa
sites in foam cells over T0901317-treated cells, which we
subsumed as foam cell-specific set. Forty-five per cent of
LXRa peaks (1193 peaks) were shared among all cell
models, which we termed shared peak set. Open chroma-
tin is associated with active transcriptional regulators and
pre-determines transcription factor binding (42,43). Using
FAIRE-seq analysis, we observed pronounced chromatin
openness of LXRa loci of shared binding sites and
T0901317-specific binding sites compared with foam cell-
specific–binding sites, similarly in all cell models
Figure 2. Differential LXRa-binding sites in human macrophage and foam cell models. (A) Comparative LXRa ChIP-seq enrichment heatmap and
mean tag density ±1.5 kb from peak center. Peaks were sorted according to their degree of variability, calculated as log2 fold-change between
models. The following sets were defined: i) T0901317-specific set (29%); ii) all models that share similar LXRa enrichment are referred to as shared
peaks (45%); iii) foam cell-specific peak set (26%). Additionally to the LXRa ChIP-seq, we also plotted the average chromatin openness of the three
peak sets derived from FAIRE-seq analyses. Macrophages are represented in grey, T0901317-treated macrophages in brown, foam cells in green,
T0901317-treated foam cells in blue and average FAIRE in black. (B) Representative tag alignment tracks of LXRa ChIP-seq, which were
normalized against IgG control lane tags of same loci. Set-specific examples of genomic regions with differential or shared LXRa binding in our
models. APOC1 locus (T0901317 specific set), LXR locus (shared set) and PARP1 locus (foam cell specific set). Arrows indicate transcription start
sites and orientation of transcription. Black arrows under tracks show peaks.
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(Figure 2A and Supplementary Figure S2A). Further, we
observed that open LXRa-binding sites were enriched
with other co-localized transcription factor-binding sites
(TFBS, data extracted from Encode) compared with
oxysterol-induced foam cell-specific–binding sites
(Supplementary Figure S2A, TFBS). Although T0901317
treatment apparently induced LXRa and co-activator
assembly at highly accessible transcriptional hotspots,
oxLDL treatment seemed to trigger less pronounced
LXRa binding to DNA. As shown in Figure 2B and
Supplementary Figure S2B and C, characteristic loci for
each set of the LXRa-binding site included the
well-known LXRa target genes ABCA1, LXR itself and
the APOE/C2/C4-gene cluster, or unexpected new target
genes as poly(ADP-ribose)polymerase-1, PARP1 or pre-
B-cell leukemia homeobox 4, PBX4.
LXRa peak enrichment at transcriptional start sites of
target genes is sharpened by T0901317 treatment
To further characterize shared and differential LXRa-
binding sites, we performed de novo motif search for
each of the three sets of specific LXRa genomic sites.
Only in the shared and T0901317-specific LXRa peak
sets we found significant enrichment of the direct repeat
spacer 4 (DR4) motif, which is known from targeted gene
analyses [Figure 3A, (44)]. In contrast, the foam cell-
specific set of LXRa-binding site sequences did not signifi-
cantly enrich any motif. Similar was true for the targeted
scanning of de novo extracted LXR:RXR motif from the
shared peak set. With a fairly stringent P-value cut-off of
10e-4, we found that 15% (398 peaks) of all LXRa-
binding sites occupied this DR4 motif, but only 2%
thereof were derived from foam cell-specific set
(Supplementary Figure S3A). To biochemically character-
ize the derived de novo consensus LXR:RXR motif, we
performed transient reporter gene assays (Supplementary
Figure S3B). Surprisingly, single-nucleotide mutations of
LXR response elements did hardly change reporter gene
activity. Major mutations in LXRa halfsites were required
to significantly decrease reporter activity. These observa-
tions were consistent with other nuclear receptor studies,
suggesting that LXRa could bind to fairly degenerated
DR elements (19,39).
We also tested the observed higher degree of conserva-
tion in the spacer region at positions 8 and 9. Mutations in
the spacer region resulted in a strong decrease of reporter
gene expression, indicating potential stereochemical dis-
turbance of LXRa binding.
To further analyse the spatial characteristics of LXRa
binding, we determined the genomic positions of LXRa-
binding sites. This analysis revealed that T0901317-
induced LXRa binding increased enrichments around
transcription start sites and promoters, whereas oxysterol
induced foam cell specific LXRa binding sites were en-
riched downstream of genes (Figure 3B). This analysis
suggested a more pronounced shaping of transcriptional
initiation by the nanomolar binding ligand T0901317 in
contrast to only micromolar binding by natural sterols.
To study the effects of genome-wide LXRa binding on
transcriptional networks, we performed gene expression
and LXR knockdown analyses of the investigated
cellular models. By correlating the differentially expressed
target genes (P 0.05 versus macrophage) with the
genome-wide LXRa binding map, 19% of the LXRa-
binding sites overlapped with differentially expressed
genes, thereof 8% were associated with 186 genes that
were significantly sensitive to LXR knockdown
(Figure 3C, stringent set). The observed enrichment of
differentially expressed genes close to LXRa-binding
sites was statistically significant (P< 0.005 for K–S test
and hypergeometric test and P< 0.01 for ECDF test)
and was absent in a randomly shuffled set of binding
sites (Supplementary Figure S3C).
In addition to gene expression data, we generated for all
cell models genome-wide maps from histone modifications
H3K4me3 and H4K20me1, which are important tran-
scriptional initiation or elongation marks, respectively
(45). Combined with FAIRE-seq data of open chromatin,
we determined promoter-specific changes of potential
LXRa target genes that harbour enriched LXRa-binding
sites. These changes correlated well with gene expression
profiles [Supplementary Figure S3D and E, (25)] and
could be used to identify 492 additional LXRa target
genes. This approach further increased the total correl-
ation of LXRa-binding sites with target genes to 30%
(Figure 3C). Correlation analysis between gene expression
and LXRa peak enrichment at differentially regulated
LXRa target genes revealed a bimodal regulation of
gene expression in all cell models (Figure 3D).
Expression levels separated in quantiles showed increased
LXRa-binding enrichment in quantiles 2 to 4 and 2 to
3. Remarkably, expression quantile 4 in all cell models was
correlated with decreased LXRa peak enrichment, sug-
gesting minor effects of LXRa on this gene set.
Despite similar expression profiles, we observed less
enriched LXRa binding at differentially regulated target
genes in untreated foam cells compared with T0901317-
treated foam cells. This was also consistent with men-
tioned observations of less efficient positioning of LXRa
binding to promoter sites and DR4 sequence motifs.
Taken together, we observed a bimodal expression
profile in all described cell models with less pronounced
binding properties in foam cells, which could be substan-
tially sharpened by T0901317 treatment.
Main functions of LXRa in cholesterol metabolism,
apoptosis and interaction with the PPARa signalling
pathway
For the functional annotation, we first analysed the strin-
gently validated set of 186 knockdown-sensitive LXRa
target genes and deciphered specific pathways enriched
in foam cells, T0901317-foam cells and T0901317-treated
macrophages (Supplementary Table S2). In vehicle-
treated foam cells, we discovered ‘‘organic acid biosyn-
thetic process’’ and ‘‘regulation of cholesterol storage’’.
Further, we found 14 genes associated with the regulation
of apoptosis, indicating increasing cell death that could
contribute to the formation of atherosclerotic plaques in
vivo. Foam cells treated with the synthetic LXRa ligand
T0901317 did not significantly enrich this disease-
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associated pathway. Instead they showed enrichment of
the BIOCARTA pathway ‘‘nuclear receptors in lipid
metabolism and toxicity’’, and the bioprocess ‘‘negative
regulation of cholesterol storage’’, which is one of the
main functions of this anti-atherogenic compound.
Interestingly, the PPARa signalling pathway was
enriched in T0901317-treated and -untreated foam cells,
indicating tight interactions of LXRa- and
PPARa-regulated pathways, as reported recently for
macrophages (39). Further investigation of the involve-
ment of LXRa in PPARa signalling pathway in
T0901317-treated foam cells revealed a major proportion
of shared target genes (Supplementary Figure S4).
Strikingly, the LXRa complex also regulated the expres-
sion of two major co-activators of PPARa, Cbp/p300
interacting transactivator with Glu/Asp-rich carboxy
terminal domain 2 (CITED2) and peroxisomal
proliferator-activated receptor A interacting complex 285
(PRIC 285). For set-specific functional annotation, we
found similar results as for the stringent set of LXRa
target genes (Supplementary Table S3), with the addition
of defence response enrichment in shared peak set and the
involvement of Ras protein signal transduction in foam
cell-specific peaks set.
LXRa binding and genetic variants associated with
complex diseases reveal key target genes in transcriptional
networks
Numerous genome-wide association studies (GWAS)
were successful in associating genetic variants and
genomic loci to common diseases (46). But in many
cases, genetic variation associated to disease phenotypes
could not functionally explain the underlying mechanisms.
To discover the potential impact of genetically influenced
Figure 3. Differential binding but shared gene expression properties in T0901317-treated and -untreated foam cells. (A) De novo motif analyses.
Motif enrichment was analysed with the top 100 ChIP-seq sequences from the three peak sets followed by TRANSFAC motif search. (B) Genomic
positions of LXRa peaks. Fold-change of LXRa peak distribution was compared with genome composition for each differential peak set. The
following features are shown from left to right: promoter 1 kb, promoter 1–2 kb, promoter 2–3 kb, downstream 1 kb, downstream 1–2 kb,
downstream 2–3 kb, 50–untranslated region (UTR), 30 UTR, coding exon, distal intergenic and intron. (C) Distribution of all LXRa-binding sites
over the human genome and association with gene expression. Peaks that are located in an area with no genes ±200 kb (grey), peaks annotated to
near genes (distance <200 kb) without indication of differential expression (compared with ligand-free macrophage) (blue). All peaks annotated to
near genes (distance <200 kb) with indication of differential expression (white) including peaks near differentially expressed genes (orange), peaks
near LXR knockdown-sensitive genes (8%, stringent set) and peaks near genes that showed a relevant chromatin modification change at the
transcriptional start site (light blue). (D) Correlation of differential expression fold-change (separated in 4 up- and 4 down- quantiles) with
normalised LXRa peak enrichment for T0901317-treated macrophages (brown), T0901317-treated foam cells (blue) and foam cells (green).
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LXRa-induced transcriptional networks on complex
diseases, we searched for significant, disease relevant
SNPs. We considered SNPs in linkage disequilibrium of
cell model-specific LXRa-dependent–binding sites that
showed differentially expressed target genes. As listed in
Table 1, we found a number of LXRa-dependent genes
with central impact on metabolism and inflammation. The
new LXRa target gene homeobox protein PBX4
(Supplementary Figure S2C) showed striking association
with LDL cholesterol metabolism, whereas another LXRa
target gene, the LDL-associated phospholipase A2
(PLA2G7) was associated with ‘‘lipoprotein-associated
lipase activity and mass’’. The most striking connection
between LXRa binding and disease related loci was
found with SNP rs4420638, which was associated to
‘‘C-reactive protein’’ with a P-value of 9e-139 and ‘‘LDL
cholesterol’’ with a P-value of 1e-60 in meta-analyses
(Table 1). The SNP rs4420638 is located close to the tran-
scription termination site of APOC1 and is encircled by
two LXRa-binding sites that are in 5.7- and 6.5-kb
distance (Figure 4A). LXRa-binding peaks detected at
this locus were T0901317 specific (Figures 2B and 4A),
whereas the natural ligand oxLDL was not efficient in
recruiting LXRa to this locus. Consistently, T0901317
treatment led to an improved expression profile of the
whole-gene cluster (Supplementary Figure S5). In this
context, it is interesting to note that APOC1 gene is not
only located within a cluster of genes that are implicated
in plasma lipid metabolism [APOE, APOC4 and APOC2,
(47)] but also surrounded by genes (BCL3, RELB,
PVRL2) that are involved in biological processes, such
as inflammation, immunity, differentiation, cell growth,
tumorigenesis and apoptosis (first two via NF-kB
signalling). To provide a frame on the global impact of
APOC1 and surrounding genes on lipid metabolism and
inflammatory response, we performed transcriptional
network analysis of this LXRa locus. To embed the
gene cluster around APOC1 into a broader metabolic
context, we further considered well-known LXRa target
genes and generated a network with differential expression
data of the foam cell using the STRING database (Figure
4B). This network illustrated the tight relationship
between direct and indirect LXRa target genes in foam
cells and their involvement in major processes, such as
lipid metabolism, inflammation and apoptosis. Thus, we
can conclude that LXRa-dependent activation of the
APOE/C1/C4/C2 cluster supported lowering cholesterol
levels (48) by triggering a defined network of genes.
Atheroprotective potential of 32 novel LXRa target genes
in T0901317-treated foam cells
The atheroprotective potential of the synthetic LXRa
ligand T0901317 has been previously shown, but the
underlying gene networks were only partly understood
Table 1. Correlation of LXRa-binding data with GWAS
Function Disease/term SNP P-value Genes Distance
to SNP (kb)
Metabolism LDL cholesterol rs10401969 2.0E-08 PBX4 311.5
rs4420638 1.0E-60 APOC1 5.7
rs2142672 2.0E-08 MYLIP 52.1
Triglycerides rs17216525 4.0E-11 PBX4 57.0
rs4420638 3.0E-13 APOC1 5.7
rs7679 7.0E-11
PLTP
33.3
HDL cholesterol rs7679 4.0E-09 33.3
Lipoprotein-associated phospholipase A2 activity and mass rs1805017 6.0E-14 PLA2G7 40.4
Inflammation Mean platelet volume rs12485738 6.0E-31 ARHGEF3 16.0
Rheumatoid arthritis rs2062583 2.0E-06 84.4
C-reactive protein rs4420638 9.0E-139 APOC1 5.7
Heart Myocardial infarction (early onset) rs9982601 6.0E-11
MRPS6
17.2
Coronary heart disease rs9982601 4.0E-10 17.2
rs7801190 3.0E-08 SLC12A9 53.6
rs10512597 8.0E-11 CD300LF 135.3
D-dimer levels rs2774920 1.0E-06 ABCA4 164.3
Resting heart rate rs314370 6.0E-10 SLC12A9 58.5
Diastolic blood pressure rs1530440 1.0E-09 ARID5B 153.4
Brain Alzheimer’s disease rs4420638 2.0E-44 APOC1 5.7
Information processing speed rs6051520 2.0E-07 TRIB3 6.2
Multiple sclerosis rs17174870 1.0E-08 MERTK 93.7
Amyloid A levels rs2896526 4.0E-22 LDHA 92.5
Skin Melanoma rs3219090 9.0E-08 PARP1 72.9
rs2230926 1.0E-17
TNFAIP3
36.6
Psoriasis rs610604 9.0E-12 33.2
For screening potential overlaps between LXRa-binding sites and validated SNPs that were genetically associated with common diseases, we chose
the NHGRI GWAS catalogue. We considered only those LXRa target sites that were within LD to the reported SNPs. Columns indicate the general
category, associated diseases or terms and the SNP ID. The P-value indicates the degree of certainty of disease association of the SNP. Next column
depicts the reported and potentially disease relevant genes in proximity to the associated SNP. The last column shows the distance between LXRa
binding sites and SNPs within the LD block, presented in kilobases (kb).
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(49). First, we analysed the direct effects of LXRa binding
and their further subsequent impact on foam cell develop-
ment. Therefore, we selected differentially expressed and
LXR knockdown-validated target genes in foam cells and
generated a network with interaction data from the
FANTOM and STRING database (Figure 5A). The
introduced oxLDL stimulus led to activation of 160
genes and repression of 93 genes. The involvement of
various transcription factors such as CCAAT-
enhancer-binding proteins CEBPB and CEBPG or
NF-kB1 illustrated once more the broad impact of
ligand-induced LXRa activation on multiple metabolic
processes regulated by LXRa itself, interacting transcrip-
tion factors and other genes. For functional classification,
we applied Ingenuity Pathway Analysis (IPA) and could
annotate molecular functions, such as lipid metabolism,
inflammation and cell death. The apoptotic function of
these cells was already observed in the stringent set of
LXRa target genes (Supplementary Table S2). In the
next step, we performed differential expression analysis
of T0901317-treated foam cells compared with untreated,
diseased foam cells. We selected LXR knockdown-sensi-
tive genes with LXRa binding site in this model and
obtained 32 novel LXRa target genes and six previously
described genes. We subjected all 38 genes to IPA and
obtained the most enriched network functions in carbohy-
drate metabolism, molecular transport and lipid metabol-
ism (Figure 5B and Supplementary Figure S6A). To gain
more insight in the involvement of the underlying genes in
classical LXR/RXR activation pathway (IPA top canon-
ical pathway P-value 1.65e-3), we performed an overlap
analysis using IPA (Figure 5C). We found two genes
directly connected with LXRa (SCD, MYLIP,
Supplementary Figure S6B) and 10 indirect interactions
in this pathway, the latter are tightly bound on inter-
actions with the nuclear factor of kappa light polypeptide
gene enhancer in B-cells (NF-kB) complex and tumour
necrosis factor-a (TNFA) signalling. Our previous analysis
revealed all 38 genes to be direct LXRa target genes,
indicating a strong bond between LXRa, NF-kB and
TNFA signalling. Interestingly, arresten [COL4A1,
collagen chain of basement membranes, (50)] and
chemokine orphan receptor 1 [CXCR7, member of the
G-protein coupled receptor family, (51)] were associated
with cardiovascular disease (IPA top disorder, P-value
1.07e-3). Both genes were significantly upregulated after
T0901317 treatment in foam cells. The highest upregula-
tion (6-fold) showed the interferon-induced
guanylate-binding protein 2 (GBP2, Supplementary
Figure S6B). This GTPase has not been previously
related to LXRa but was found to be associated with
diseases such as psoriasis, rheumatoid arthritis and experi-
mentally induced diabetes. One of the highest
downregulated (2-fold) genes was protein inhibitor of
activated STAT 4 (PIAS4, Supplementary Figure S6B),
which interacts with the NF-kB complex (52).
In summary, this analysis revealed a number of so far
unknown factors of the artheroprotective network that
were found to be enriched in functions, such as carbohy-
drate metabolism, molecular transport and lipid metabol-
ism. These new genes can be of important value for
thorough understanding and future investigations of tran-
scriptional regulation in cellular atherosclerosis processes
and ligand-specific activation of LXRa.
Figure 4. Functional connection between LXRa binding to APOE/C1/C4/C2 locus and disease-relevant SNPs. (A) UCSC genome browser picture of
the rs4420638 SNP and in linkage disequilibrium (DistiLD Database, Palleja` et al., 2011) surrounded area (chr19: 45247846-45544890). SNP position
is indicated with a black arrow on top of normalized tag alignment tracks of LXRa ChIP-seq. LXRa-binding sites (black arrows under track) around
apolipoprotein C1 gene (APOC1). LXRa enrichment in macrophages (grey), in T0901317 treated macrophages (brown), in foam cells (green) and in
T0901317-treated foam cells (blue) is depicted. (B) STRING interaction network of genes within the extended APOE/C1/C4/C2-gene cluster with
addition of well-known LXRa target genes. Differential expression of foam cells compared to macrophages is presented. Red circles indicate
upregulated genes, and blue circles show downregulated genes. Grey lines represent the STRING network confidence view. Asterisk indicates
LXR knockdown-sensitive genes. Bold circles represent genes with an enriched LXRa-binding site close by.
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DISCUSSION
Comprehensive analyses are important to decode the
complex molecular networks that underlie cell physiology
and common diseases (53). In contrast to conventional
molecular biological studies that usually focus on individ-
ual target genes of a nuclear receptor, we aimed to identify
gene networks of LXRa that coherently respond to
natural ligands or to pharmacological intervention in
foam cells and macrophages. To make the analysis most
stringent, and to largely exclude any potential off-target
effects of LXR ligands, we considered in our network
analyses only LXRa loci that showed significant effects
on gene expression and were additionally sensitive to
LXR knockdown.
In this study, we analysed humanmacrophages, which in
stark contrast to mouse macrophages show a characteristic
auto-regulatory loop of LXRa activation. In general,
studies on atherosclerotic plaque development in mouse
Figure 5. Beneficial effects of LXRa modulation with synthetic ligand T0901317 in foam cells. (A) LXRa target gene network in foam cells. The
differential expression of LXR knockdown-sensitive genes is displayed in foam cells compared with macrophages. Well-known and physiologically
relevant target genes in lipid metabolism as well as in inflammation and apoptosis are emphasized. Red circles indicate upregulated genes, and blue
circles show downregulated genes. Grey lines represent the FANTOM and STRING network. Bold circles represent genes with an enriched
LXRa-binding site close by. (B) T0901317-specific LXRa target genes in foam cells. The differential expression of LXR knockdown-sensitive
genes in T0901317 foam cells is shown compared to foam cells. Red circles display upregulated genes, and blue circles indicate downregulated
genes. Bold circles represent genes with an enriched LXRa-binding site close by. Grey lines represent LXR knockdown-validated interaction with
LXRa. The top associated network functions assigned by IPA are carbohydrate metabolism, molecular transport and lipid metabolism. (C) LXR/
RXR activation pathway with direct involvement of T0901317-specific LXRa target genes from associated IPA network in foam cells. The differ-
ential gene expression of knockdown-sensitive LXRa target genes on T0901317 treatment in foam cells compared to untreated foam cells are
visualized in red for significantly upregulated genes and in blue for significantly downregulated genes. Unregulated gene expression of central
gene products is displayed in white. Bold circles represent an enriched LXRa-binding site near the gene.
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can only be partly adapted for understanding human ath-
erosclerosis involving mainly smaller arteries instead of the
large vessels that are analysed in mice (54). The human
THP1 cell line applied here is a widely used macrophage
model for human foam cell development (55). Consistent
with numerous reports, we could largely observe similar
effects in THP1 and primary macrophages on LXRa-
binding or gene expression patterns. The standardised
THP1 cell line allowed our comprehensive analyses,
which would have been difficult with primary cells.
Nuclear receptors, such as LXRa, react to various
environmental factors to adapt metabolic and other
cellular pathways. With the rise of genome-wide binding
studies, the classic model of nuclear receptor transactiva-
tion was challenged by recent findings (19,39,56,57). The
alternative activation mode, observed in these studies,
included a complex interplay between ligands, pioneer
factors, co-regulators and histone modifications.
According to the alternative activation mode, in absence
of a specific ligand, the chromatin has a more closed struc-
ture and is less accessible for nuclear receptor binding,
which changes rapidly upon ligand activation (58). In
contrast to a mixed-binding pattern of basal and
induced LXRa binding, we observed ligand requirement
for all significant binding sites. The few observed ligand-
independent, basal-binding sites were not significantly
enriched and eliminated during filtering. This observation
was confirmed by the overall low protein amount in
macrophages in absence of a ligand. For example, using
ChIP-seq we did not detect LXRa binding in absence of a
ligand in the ABCA1 locus. To rule out sensitivity issues,
we tested among others the ABCA1 and ABCG1 loci with
ChIP–qPCR and observed that these loci were clearly in-
creasingly occupied by LXRa upon T0901317 treatment.
In absence of a ligand, we detected only spurious LXRa
binding, which was mostly in the range of negative control
binding sites. This result differs from recent findings from
Jakobsson et al. (59), who applied a subtype unspecific
LXR antibody and performed endpoint ChIP–PCR
analyses, which may lead to different results in terms of
accurate relative quantification compared with ChIP–
qPCR using real-time detection as applied in this study.
As shown here, the evolutionary rather new nuclear
receptor LXRa features comparably poor defined se-
quence specificity but increased flexibility with regard to
natural ligand activation including compounds derived
from food. Consistently, we detected differential LXRa-
binding patterns in foam cells, in T09011317-treated foam
cells that contained also oxysterols, and in normal macro-
phages. Dependent on the individual requirements of the
macrophage or the foam cell, LXRa seemed to bind with
individual intensity to target gene sites. In the case of foam
cell-specific–binding sites, we detected less pronounced,
almost DR4 motif-independent and promoter-distant–
binding patterns. There are multiple mechanisms that
could explain this specific recruitment, including
stabilizing interactions with other transcription factors
(39) via looping or ‘piggyback’ binding, or assisted
binding through specifically modified histones with an
open chromatin environment (60).
In contrast to the shared and T0901317-specific peaks at
known lipid metabolism relevant target genes LXRa and
APOC1, we discovered for the foam cell-specific peaks
unexpected gene loci: for example the novel LXRa
target gene PARP1, which represents an enzyme that is
known to be involved in DNA damage repair. Recently, it
has been shown that inhibition of PARP1 leads in particu-
lar in brown adipose tissue and skeletal muscle to
enhanced mitochondrial metabolism via activation of the
histone deacetylase SIRT1, which culminates in protection
against metabolic disease (61). Interestingly, in diseased
foam cells, we detected increased oxLDL triggered
LXRa binding at the PARP1 locus but striking absence
of LXRa binding at this locus under T0901317 therapy.
Thus, LXRa modulation by an efficient synthetic LXR
ligand may play a so far unexplored role in counteracting
the effects of (basal) PARP1 gene binding effects of
oxLDL-activated LXRa.
Recent changes in human life style and nutrition may
overstrain the natural balance in foam cells to reverse
cholesterol transport. The synthetic LXRa ligand was
more efficient in triggering sequence-specific binding and
thereby controlling more stringently LXRa transcrip-
tional regulation. This genome-wide effect form increased
atheroprotective effects. In summary, we identified
disease-causing and pharmacologically treatable gene
networks that can be modulated by specific intervention.
Altogether, we found 32 novel LXRa target genes with
atheroprotective potential. In contrast to natural
oxysterols, T0901317 treatment resulted in striking
binding of LXRa at the APOE/C1/C4/C2-gene cluster
and its surrounding genes. This genomic region has been
found to be highly significantly associated with the disease
terms ‘‘LDL-cholesterol’’ and ‘‘C-reactive protein’’, which
suggests that specific ligand-induced LXRa binding—in
conjunction with other transcriptional regulators—at
this locus is important for establishing a key network of
cholesterol transport and anti-inflammatory genes.
Quantitative LXRa-binding studies using clinical
samples of diseased patients and control subjects may
reveal sequence-dependent variation in LXRa binding
efficiency, and thus explain the functional impact of
genetic variation in the APOE/C1/C4/C2-gene locus for
cardiovascular or other diseases.
We have generated LXRa genomic loci and related ex-
pression data in human foam cells, which may also
provide a resource for developing further mechanistic
studies, including the use of alternative small molecule
activators of LXR, such as GW3965 (62) to analyse
ligand-dependent fine-tuning of LXR-regulated gene ex-
pression via differential co-factor recruitment.
In summary, our data revealed an LXRa ligand-
dependent network of transcriptional regulation, which
is vulnerable to molecules that efficiently activate LXRa
and shape gene expression patterns. Single gene analysis
approaches may hit the limits of reductionism when bio-
logical function emerges on the interaction network level
of genes or gene products (63). Although genome-wide
DNA binding of LXRa may be deduced from binding
or reporter gene assay efficiencies, expression can vary
because of ligand-dependent differential interaction with
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further transcriptional co-factors leading to varying
response on the gene network level (24).
Integration of gene, protein or metabolic networks
(64,65), will potentially generate an additional layer of
complementary information to provide an even more
comprehensive understanding of complex interconnected
molecular pathways in cell metabolism during atherogen-
esis and to optimize treatment of cardiovascular disease.
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